Eagle Rock Investment Company’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-30,000
Closed -$335K 136
2022
Q4
$335K Hold
30,000
0.08% 113
2022
Q3
$242K Hold
30,000
0.06% 112
2022
Q2
$226K Hold
30,000
0.06% 114
2022
Q1
$282K Buy
30,000
+5,000
+20% +$41.7K 0.06% 100
2021
Q4
$200K Buy
+25,000
New +$226K 0.04% 102

Other funds holding TEVA

Eagle Rock Investment Company's TEVA Position: Q1 2023 in Review

Eagle Rock Investment Company sold out of Teva Pharmaceuticals (TEVA) in Q1 2023, closing a stake of 30,000 shares — an estimated $335K sold.

Eagle Rock Investment Company first reported a position in TEVA in Q4 2021 and held it in 5 quarters. The position peaked at $335K in Q4 2022. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2023.

  • Eagle Rock Investment Company reported no remaining Teva Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Eagle Rock Investment Company sold 30,000 Teva Pharmaceuticals shares in Q1 2023, an estimated $335K.
  • Eagle Rock Investment Company first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Eagle Rock Investment Company's Teva Pharmaceuticals position peaked at $335K in Q4 2022.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2023.

Based on Eagle Rock Investment Company's 13F filing for Q1 2023, filed 10 Apr 2023.